What is Wedbush’s Forecast for EWTX FY2026 Earnings?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Investment analysts at Wedbush reduced their FY2026 earnings estimates for Edgewise Therapeutics in a note issued to investors on Monday, March 3rd. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($2.25) per share for the year, down from their prior forecast of ($2.24). Wedbush has a “Outperform” rating and a $45.00 price objective on the stock. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share. Wedbush also issued estimates for Edgewise Therapeutics’ FY2029 earnings at $3.99 EPS.

Several other research analysts also recently issued reports on EWTX. Evercore ISI upped their price target on shares of Edgewise Therapeutics from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $56.00 target price on shares of Edgewise Therapeutics in a research report on Tuesday. Stifel Nicolaus began coverage on shares of Edgewise Therapeutics in a report on Wednesday, January 22nd. They issued a “hold” rating and a $30.00 price target for the company. Finally, Truist Financial boosted their price objective on shares of Edgewise Therapeutics from $33.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, November 27th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $44.71.

Edgewise Therapeutics Stock Performance

Shares of EWTX stock opened at $26.71 on Thursday. Edgewise Therapeutics has a 52 week low of $14.90 and a 52 week high of $38.12. The stock has a market capitalization of $2.53 billion, a PE ratio of -17.81 and a beta of 0.20. The stock’s fifty day moving average is $26.81 and its 200-day moving average is $27.76.

Edgewise Therapeutics (NASDAQ:EWTX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03).

Insiders Place Their Bets

In related news, CEO Kevin Koch sold 8,636 shares of Edgewise Therapeutics stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $30.03, for a total transaction of $259,339.08. Following the completion of the sale, the chief executive officer now directly owns 14,478 shares of the company’s stock, valued at $434,774.34. The trade was a 37.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Alan J. Russell sold 1,200 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $30.13, for a total value of $36,156.00. Following the transaction, the insider now owns 14,863 shares in the company, valued at approximately $447,822.19. This trade represents a 7.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 164,545 shares of company stock valued at $4,605,305. Company insiders own 24.11% of the company’s stock.

Hedge Funds Weigh In On Edgewise Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in EWTX. Braidwell LP bought a new position in Edgewise Therapeutics during the third quarter worth about $52,267,000. Janus Henderson Group PLC raised its position in shares of Edgewise Therapeutics by 74.8% during the third quarter. Janus Henderson Group PLC now owns 4,558,519 shares of the company’s stock worth $121,616,000 after purchasing an additional 1,951,220 shares during the period. Paradigm Biocapital Advisors LP grew its position in shares of Edgewise Therapeutics by 61.1% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,493,929 shares of the company’s stock valued at $119,988,000 after purchasing an additional 1,704,757 shares during the period. First Light Asset Management LLC bought a new stake in Edgewise Therapeutics during the 4th quarter worth approximately $20,843,000. Finally, Foresite Capital Management VI LLC bought a new stake in Edgewise Therapeutics during the 4th quarter worth approximately $15,620,000.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.